(Q51107497)

30 March 2018

title

A phase II trial of deferoxamine in patients with hormone-refractory metastatic prostate cancer. (English)

1 reference

30 March 2018

main subject

phase II clinical trial

0 references

1 reference

Dreicer R

1

1 reference

30 March 2018

Kemp JD

2

1 reference

30 March 2018

Stegink LD

3

1 reference

30 March 2018

Cardillo T

4

1 reference

30 March 2018

Davis CS

5

1 reference

30 March 2018

Forest PK

6

1 reference

30 March 2018

See WA

7

1 reference

30 March 2018

publication date

1 January 1997

1 reference

30 March 2018

published in

Cancer Investigation

1 reference

30 March 2018

volume

15

1 reference

30 March 2018

issue

4

1 reference

30 March 2018

page(s)

311-317

1 reference

30 March 2018

The effect of desferrioxamine on transferrin receptors, the cell cycle and growth rates of human leukaemic cells

cites work

1 reference

https://api.crossref.org/works/10.3109%2F07357909709039731

Stimulation of human prostatic carcinoma cell growth by factors present in human bone marrow

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909709039731

Selective stimulation of prostatic carcinoma cell proliferation by transferrin

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909709039731

The quantitative relationship of urinary peptide hydroxyproline excretion to collagen degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909709039731

Relevance of hydroxyproline excretion to bone metastasis in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909709039731

Modulation of deferoxamine toxicity and clearance by covalent attachment to biocompatible polymers

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909709039731

Intestinal absorption of aspartame decomposition products in adult rats

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909709039731

Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909709039731

The McGill Pain Questionnaire: Major properties and scoring methods

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909709039731

The development of a method for assessing the quality of life of cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909709039731

Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909709039731

Suramin, an active drug for prostate cancer: interim observations in a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909709039731

Transferrin receptor expression in adenocarcinoma of the lung as a histopathologic indicator of prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909709039731

10.3109/07357909709039731

21 January 2018

Identifiers

DOI

1 reference

30 March 2018

1 reference

30 March 2018